The EDGE

Dirk Willem van Bekkum: a pioneer in haematology, transplantation and radiobiology (1925–2015)

Robert Peter Gale and Bob Löwenberg

Leukemia 2015 29: 2275-2276; 10.1038/leu.2015.224

Original Articles

ACUTE MYELOID LEUKEMIA

Lithium chloride antileukemic activity in acute promyelocytic leukemia is GSK-3 and MEK/ERK dependent

F Zassadowski, K Pokorna, N Ferre, F Guidez, L Llopis, O Chourbagi, M Chopin, J Poupon, P Fenaux, R Ann Padua, M Pla, C Chomienne and B Cassinat

Leukemia 2015 29: 2277-2284; advance online publication, June 25, 2015; 10.1038/leu.2015.159

Coordinate regulation of residual bone marrow function by paracrine trafficking of AML exosomes

J Huan, N I Hornick, N A Goloviznina, A N Kamimae- Lanning, L L David, P A Wilmarth, T Mori, J R Chevillet, A Narla, C T Roberts, Jr, M M Loriaux, B H Chang and P Kurre

Leukemia 2015 29: 2285-2295; advance online publication, June 25, 2015; 10.1038/leu.2015.163

The novel function of CD82 and its impact on BCL2L12 via AKT/STAT5 signal pathway in acute myelogenous leukemia cells

C Nishioka, T Ikezoe, A Takeuchi, A Nobumoto, M Tsuda and A Yokoyama

Leukemia 2015 29: 2296-2306; advance online publication, August 11, 2015; 10.1038/leu.2015.219

ACUTE LYMPHOBLASTIC LEUKEMIA

Effects of p38α/β inhibition on acute lymphoblastic leukemia proliferation and survival in vivo

A Alsadeq, S Strube, S Krause, M Carlet, I Jeremias, C Vokuhl, S Loges, J A Aguirre-Ghiso, A Trauzold, G Cario, M Stanulla, M Schrappe and D M Schewe

Leukemia 2015 29: 2307-2316; advance online publication, June 24, 2015; 10.1038/leu.2015.153

Characterization of the genome-wide TLX1 binding profile in T-cell acute lymphoblastic leukemia

K Durinck, W Van Loocke, J Van der Meulen, I Van de Walle, M Ongenaert, P Rondou, A Wallaert, C E de Bock, N Van Roy, B Poppe, J Cools, J Soulier, T Taghon, F Speleman and P Van Vlierberghe

Leukemia 2015 29: 2317-2327; advance online publication, June 25, 2015; 10.1038/leu.2015.162

CHRONIC MYELOGENOUS LEUKEMIA

β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia

A M Eiring, J S Khorashad, D J Anderson, F Yu, H M Redwine, C C Mason, K R Reynolds, P M Clair, K C Gantz, T Y Zhang, A D Pomicter, I L Kraft, A D Bowler, K Johnson, M Mac Partlin, T O'Hare and M W Deininger

Leukemia 2015 29: 2328-2337; advance online publication, July 23, 2015; 10.1038/leu.2015.196

MULTIPLE MYELOMA, GAMMOPATHIES

Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia

I M Ghobrial, R Redd, P Armand, R Banwait, E Boswell, S Chuma, D Huynh, A Sacco, A M Roccaro, A Perilla-Glen, K Noonan, M MacNabb, H Leblebjian, D Warren, P Henrick, J J Castillo, P G Richardson, J Matous, E Weller and S P Treon

Leukemia 2015 29: 2338-2346; advance online publication, July 3, 2015; 10.1038/leu.2015.164

MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib

Z Xie, C Bi, J Y Chooi, Z L Chan, N Mustafa and W J Chng

Leukemia 2015 29: 2347-2354; advance online publication, June 30, 2015; 10.1038/leu.2015.169

CHRONIC MYLEPROLIFERATIVE NEOPLASMS

A point mutation of zebrafish c-cbl gene in the ring finger domain produces a phenotype mimicking human myeloproliferative disease

X Peng, M Dong, L Ma, X-E Jia, J Mao, C Jin, Y Chen, L Gao, X Liu, K Ma, L Wang, T Du, Y Jin, Q Huang, K Li, L I Zon, T Liu, M Deng, Y Zhou, X Xi, Y Zhou and S Chen

Leukemia 2015 29: 2355-2365; advance online publication, June 24, 2015; 10.1038/leu.2015.154

Loss of HIF-1α accelerates murine FLT-3^ITD-induced myeloproliferative neoplasia

T Velasco-Hernandez, D Tornero and J Cammenga

Leukemia 2015 29: 2366-2374; advance online publication, June 24, 2015; 10.1038/leu.2015.156

STEM CELL TRANSPLANTATION

Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML)

A Pigneux, M Labopin, J Maertens, C Cordonnier, L Volin, G Socié, D Blaise, C Craddock, N Milpied, U Bacher, F Malard, J Esteve, A Nagler and M Mohty on Behalf of the Acute Leukemia Working Party EBMT

Leukemia 2015 29: 2375-2381; advance online publication, June 17, 2015; 10.1038/leu.2015.143

MECHANISMS OF RESISTANCE

Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia

I-K Park, B Mundy-Bosse, S P Whitman, X Zhang, S L Warner, D J Bearss, W Blum, G Marcucci and M A Caligiuri

Leukemia 2015 29: 2382-2389; advance online publication, June 19, 2015; 10.1038/leu.2015.147

FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors

C C Smith, K Lin, A Stecula, A Sali and N P Shah

Leukemia 2015 29: 2390-2392; advance online publication, June 25, 2015; 10.1038/leu.2015.165

IMMUNOTHERAPY

Antileukemia multifunctionality of CD4⁺ T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer

H Fujiwara, T Ochi, F Ochi, Y Miyazaki, H Asai, M Narita, S Okamoto, J Mineno, K Kuzushima, H Shiku and M Yasukawa

Leukemia 2015 29: 2393-2401; advance online publication, June 24, 2015; 10.1038/leu.2015.155

Letters To The Editor

Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib

K Wenn, L Tomala, S Wilop, L Vankann, C Hasenbank, O Frank, A Hochhaus, F J Giles, T Lange, M C Müller, S Koschmieder, F Beier, P Ziegler and T H Brümmendorf

Leukemia 2015 29: 2402-2404; advance online publication, September 15, 2015; 10.1038/leu.2015.245

Acquired isodisomy on chromosome 13 at diagnosis results in impaired overall survival in patients with FLT3-ITD mutant acute myeloid leukaemia

J C T Loke, S Akiki, J Borrow, J Ewing, S W Bokhari, D Chandra, J Arrazi, P Hazlewood, K Arthur, J Walsh, Y Membwange, F A Wandroo, A Watts, A Borg, K Brock, P Ferguson, C Craddock, M Griffiths and M Raghavan

Leukemia 2015 29: 2404-2407; advance online publication, June 19, 2015; 10.1038/leu.2015.148

Mutational profile of childhood myeloproliferative neoplasms

A Karow, R Nienhold, P Lundberg, E Peroni, M C Putti, M L Randi and R C Skoda

Leukemia 2015 29: 2407-2409; advance online publication, July 30, 2015; 10.1038/leu.2015.205

Constitutional genetic association with CALR mutations?

L Eder-Azanza, P Evans, C Wickham, S Akiki, J L Vizmanos, A Chase and N C P Cross

Leukemia 2015 29: 2410-2411; advance online publication, July 22, 2015; 10.1038/leu.2015.186

Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial

J C Strefford, L Kadalayil, J Forster, M J J Rose-Zerilli, A Parker, T T Lin, N Heppel, K Norris, A Gardiner, Z Davies, D Gonzalez de Castro, M Else, A J Steele, H Parker, T Stankovic, C Pepper, C Fegan, D Baird, A Collins, D Catovsky and D G Oscier

Leukemia 2015 29: 2411-2414; advance online publication, August 10, 2015; 10.1038/leu.2015.217

Long-term complete clinical and hematological responses of the TEMPI syndrome after autologous stem cell transplantation

S S Kenderian, F G Rosado, D B Sykes, J D Hoyer and M Q Lacy

Leukemia 2015 29: 2414-2416; advance online publication, October 26, 2015; 10.1038/leu.2015.298

Clarification of the definition of complete response in multiple myeloma

B G M Durie, J F S Miguel, J Blade and S V Rajkumar on behalf of the International Myeloma Working Group

Leukemia 2015 29: 2416-2417; advance online publication, October 21, 2015; 10.1038/leu.2015.290

Illness and artistic creativity (on the 70th anniversary of the death of Béla Bartók, composer, ethnomusicologist and leukemia patient)

D S Krause

Leukemia 2015 29: 2417-2418; advance online publication, August 11, 2015; 10.1038/leu.2015.221

Common genetic variants in 11q13.3 and 9q22.33 are associated with molecular subgroups of multiple myeloma

S W Erickson, O W Stephens, S S Chavan, E Tian, J Epstein, B Barlogie, C J Heuck and A J Vangsted

Leukemia 2015 29: 2418-2421; advance online publication, August 26, 2015; 10.1038/leu.2015.238

Direct comparison of quantitative digital PCR and 2-hydroxyglutarate enantiomeric ratio for IDH mutant allele frequency assessment in myeloid malignancy

D H Wiseman, E A Struys, D P Wilks, C I Clark, M W Dennis, E E W Jansen, G S Salomons and T C P Somervaille

Leukemia 2015 29: 2421-2423; advance online publication, June 19, 2015; 10.1038/leu.2015.151

Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children’s Oncology Group

M A Kutny, T A Alonzo, E R Gamazon, R B Gerbing, D Geraghty, B Lange, N A Heerema, L Sung, R Aplenc, J Franklin, S C Raimondi, B A Hirsch, A Konkashbaev, N J Cox, K Onel, A S Gamis and S Meshinchi

Leukemia 2015 29: 2424-2426; advance online publication, July 1, 2015; 10.1038/leu.2015.171

Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia

B Bilori, S Thota, M J Clemente, B Patel, A Jerez, M Afable II and J P Maciejewski

Leukemia 2015 29: 2427-2429; advance online publication, October 9, 2015; 10.1038/leu.2015.280

Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma

M Cavo, L Pantani, A Pezzi, M T Petrucci, F Patriarca, F Di Raimondo, G Marzocchi, M Galli, V Montefusco, E Zamagni, B Gamberi, P Tacchetti, A Brioli, A Palumbo and P Sonneveld

Leukemia 2015 29: 2429-2431; advance online publication, October 7, 2015; 10.1038/leu.2015.274

Presence of polyclonal hematopoiesis in females with Ph-negative myeloproliferative neoplasms

S Swierczek, L T Lima, T Tashi, S J Kim, X T Gregg and J T Prchal

Leukemia 2015 29: 2432-2434; advance online publication, September 15, 2015; 10.1038/leu.2015.249

Rare FLT3 deletion mutants may provide additional treatment options to patients with AML: an approach to individualized medicine

N Chatain, R C Perera, G Rossetti, J Rossa, P Carloni, M Schemionek, T Haferlach, T H Brümmendorf, S Schnittger and S Koschmieder

Leukemia 2015 29: 2434-2438; advance online publication, May 27, 2015; 10.1038/leu.2015.131

Adverse prognostic impact of KIT mutations in childhood CBF-AML: the results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial

M Tokumasu, C Murata, A Shimada, K Ohki, Y Hayashi, A M Saito, J Fujimoto, K Horibe, M Nagao, H Itoh, Y Kamikubo, H Nakayama, A Kinoshita, D Tomizawa, T Taga, A Tawa, S Tanaka, T Heike and S Adachi

Leukemia 2015 29: 2438-2441; advance online publication, May 15, 2015; 10.1038/leu.2015.121

The deregulated expression of miR-125b in acute myeloid leukemia is dependent on the transcription factor C/EBPα OPEN

P Vargas Romero, S Cialfi, R Palermo, C De Blasio, S Checquolo, D Bellavia, S Chiaretti, R Foà, A Amadori, A Gulino, G Zardo, C Talora and I Screpanti

Leukemia 2015 29: 2442-2445; advance online publication, May 18, 2015; 10.1038/leu.2015.117

A novel recurrent EP300–ZNF384 gene fusion in B-cell precursor acute lymphoblastic leukemia

Y Gocho, N Kiyokawa, H Ichikawa, K Nakabayashi, T Osumi, T Ishibashi, H Ueno, K Terada, K Oboki, H Sakamoto, Y Shioda, M Imai, Y Noguchi, Y Arakawa, Y Kojima, D Toyama, K Hata, T Yoshida, K Matsumoto, M Kato, T Fukushima, K Koh, A Manabe, A Ohara and from the Tokyo Children’s Cancer Study Group

Leukemia 2015 29: 2445-2448; advance online publication, May 6, 2015; 10.1038/leu.2015.111

Correspondence

Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry

A G Dinmohamed, Y van Norden, O Visser, E F M Posthuma, P C Huijgens, P Sonneveld, A A van de Loosdrecht and M Jongen-Lavrencic

Leukemia 2015 29: 2449-2451; advance online publication, September 15, 2015; 10.1038/leu.2015.220

Corrigendum

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

A F List, J M Bennett, M A Sekeres, B Skikne, T Fu, J M Shammo, S D Nimer, R D Knight and A Giagounidis on behalf of the MDS-003 Study Investigators

Leukemia 2015 29: 2452; 10.1038/leu.2015.312